Trials / Conditions / Relapse Remitting Multiple Sclerosis

Relapse Remitting Multiple Sclerosis

9 registered clinical trials studyying Relapse Remitting Multiple Sclerosis — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Efficacy and Safety of Yishen Daluo Yin Granule for Relapsing-Remitting Multiple Sclerosis NCT07029867	Ying Gao	N/A
Completed	Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Heal NCT05084638	Novartis Pharmaceuticals	Phase 4
Unknown	Immunoregulatory Effect of Microparticle Delivered STING Agonist in the Control of Experimental Autoimmune Enc NCT05705986	Thomas Jefferson University	—
Unknown	Deficient T Regulatory Cell (Treg) Function in Patients With Relapsing Remitting Multiple Sclerosis NCT04857489	Thomas Jefferson University	—
Terminated	A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-rem NCT02038049	Novartis Pharmaceuticals	Phase 2
Completed	Effect of Fingolimod on the Cardiac Autonomic Regulation in Patients With Multiple Sclerosis NCT01704183	Kuopio University Hospital	—
Completed	Safety and Efficacy Study of Copaxone Administered in Combination With N-Acetylcysteine NCT00203099	Teva Branded Pharmaceutical Products R&D, Inc.	Phase 2
Completed	Safety and Efficacy Study of Copaxone Administered in Combination With Minocycline NCT00203112	Teva Branded Pharmaceutical Products R&D, Inc.	Phase 2
Completed	A Study to Test the Effectiveness and Safety of a New Higher 40mg Dose of Copaxone® Compared to Copaxone® 20mg NCT00202982	Teva Branded Pharmaceutical Products R&D, Inc.	Phase 2